ORIC Pharmaceuticals (NASDAQ:ORIC) Earns Overweight Rating from Cantor Fitzgerald
Cantor Fitzgerald reiterated their overweight rating on shares of ORIC Pharmaceuticals (NASDAQ:ORIC – Free Report) in a research note released on Monday, Benzinga reports. Cantor Fitzgerald also issued estimates for ORIC Pharmaceuticals’ FY2024 earnings at ($1.82) EPS. Several other research analysts have also commented on the company. Wedbush reaffirmed an outperform rating and set a […]
More Stories
Worthington Steel (NYSE:WS) Releases Quarterly Earnings Results
Worthington Steel (NYSE:WS – Get Free Report) posted its quarterly earnings results on Wednesday. The company reported $0.56 earnings per...
Short Interest in Western Asset Mortgage Opportunity Fund Inc. (NYSE:DMO) Rises By 475.0%
Western Asset Mortgage Opportunity Fund Inc. (NYSE:DMO – Get Free Report) was the recipient of a significant growth in short...
John Hancock Financial Opportunities Fund (NYSE:BTO) Short Interest Up 273.2% in September
John Hancock Financial Opportunities Fund (NYSE:BTO – Get Free Report) saw a large growth in short interest during the month...
Isuzu Motors Limited (OTCMKTS:ISUZF) Short Interest Update
Isuzu Motors Limited (OTCMKTS:ISUZF – Get Free Report) saw a large increase in short interest during the month of September....
China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Sees Large Growth in Short Interest
China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC – Get Free Report) saw a significant growth in short interest during the month of...
US Foods Holding Corp. (NYSE:USFD) Receives $66.40 Consensus Target Price from Analysts
US Foods Holding Corp. (NYSE:USFD – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the eleven...